Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.4 milligram(s) - somatropin and somatropin agonists; somatropin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.6 milligram(s) - somatropin and somatropin agonists; somatropin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.8 milligram(s) - somatropin and somatropin agonists; somatropin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 2.0 milligram(s) - somatropin and somatropin agonists; somatropin

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - somatropin - powder and solvent for solution for injection - somatropin 5.3 mg/ml - pituitary and hypothalamic hormones and analogues

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 16 iu - diluent, not applicable - excipient ingredients: metacresol; water for injections - short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 20 march 2001: short stature due to decreased or failed secretion of pituitary hormone. growth distrubances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 26 november 2001: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanograms/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituit

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5.3 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 12mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 5.3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - somatropin (rbe) - powder and solvent for solution for injection - 200microgram